OnKure

OnKure is a biopharmaceutical company focused on the development of targeted small molecule drugs. Leveraging its epigenetics translational platform, it develops natural products with potential bioactivity for the treatment of various diseases, including cancer. Currently, OnKure's core product is an orally available, selective Class I histone deacetylase (HDAC) inhibitor.